Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV001073280 | SCV001238816 | uncertain significance | Retinal dystrophy | 2018-10-15 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002554652 | SCV003524056 | pathogenic | not provided | 2024-02-05 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with glycine, which is neutral and non-polar, at codon 1816 of the USH2A protein (p.Val1816Gly). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of Usher syndrome (PMID: 27460420; Invitae). ClinVar contains an entry for this variant (Variation ID: 865788). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt USH2A protein function with a negative predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV005012535 | SCV005640789 | likely pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2024-02-02 | criteria provided, single submitter | clinical testing |